KR20240009437A - 에큐벡테딘 용량 요법 - Google Patents
에큐벡테딘 용량 요법 Download PDFInfo
- Publication number
- KR20240009437A KR20240009437A KR1020237042065A KR20237042065A KR20240009437A KR 20240009437 A KR20240009437 A KR 20240009437A KR 1020237042065 A KR1020237042065 A KR 1020237042065A KR 20237042065 A KR20237042065 A KR 20237042065A KR 20240009437 A KR20240009437 A KR 20240009437A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- cancer
- dose
- administered
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382455.0 | 2021-05-19 | ||
| EP21382455 | 2021-05-19 | ||
| PCT/EP2022/063653 WO2022243482A1 (en) | 2021-05-19 | 2022-05-19 | Dosage regimens for ecubectedin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240009437A true KR20240009437A (ko) | 2024-01-22 |
Family
ID=76197383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237042065A Pending KR20240009437A (ko) | 2021-05-19 | 2022-05-19 | 에큐벡테딘 용량 요법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277705A1 (https=) |
| EP (1) | EP4340841A1 (https=) |
| JP (1) | JP2024521122A (https=) |
| KR (1) | KR20240009437A (https=) |
| CN (1) | CN117295499A (https=) |
| AU (1) | AU2022277799A1 (https=) |
| CA (1) | CA3218171A1 (https=) |
| IL (1) | IL308389A (https=) |
| MX (1) | MX2023013715A (https=) |
| TW (1) | TW202313039A (https=) |
| WO (1) | WO2022243482A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4563149A1 (en) * | 2023-11-30 | 2025-06-04 | Pharma Mar, S.A. | Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers |
| WO2025168075A1 (zh) * | 2024-02-08 | 2025-08-14 | 映恩生物科技(上海)有限公司 | 海鞘素类化合物及其应用 |
| TW202547489A (zh) | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 |
| WO2025228596A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer |
| WO2025228594A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE368461T1 (de) * | 2004-10-29 | 2007-08-15 | Pharma Mar Sa | Zusammensetzungen enthaltend ecteinascidin und einen disaccharide |
| KR102491180B1 (ko) | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
-
2022
- 2022-05-19 IL IL308389A patent/IL308389A/en unknown
- 2022-05-19 KR KR1020237042065A patent/KR20240009437A/ko active Pending
- 2022-05-19 EP EP22731103.2A patent/EP4340841A1/en active Pending
- 2022-05-19 MX MX2023013715A patent/MX2023013715A/es unknown
- 2022-05-19 AU AU2022277799A patent/AU2022277799A1/en active Pending
- 2022-05-19 JP JP2023572000A patent/JP2024521122A/ja active Pending
- 2022-05-19 WO PCT/EP2022/063653 patent/WO2022243482A1/en not_active Ceased
- 2022-05-19 TW TW111118548A patent/TW202313039A/zh unknown
- 2022-05-19 CN CN202280034530.0A patent/CN117295499A/zh active Pending
- 2022-05-19 CA CA3218171A patent/CA3218171A1/en active Pending
- 2022-05-19 US US18/560,991 patent/US20240277705A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521122A (ja) | 2024-05-28 |
| US20240277705A1 (en) | 2024-08-22 |
| CA3218171A1 (en) | 2022-11-24 |
| CN117295499A (zh) | 2023-12-26 |
| EP4340841A1 (en) | 2024-03-27 |
| WO2022243482A1 (en) | 2022-11-24 |
| MX2023013715A (es) | 2024-03-26 |
| AU2022277799A1 (en) | 2023-12-21 |
| TW202313039A (zh) | 2023-04-01 |
| IL308389A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240009437A (ko) | 에큐벡테딘 용량 요법 | |
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| DK2269604T3 (en) | Treatment of solid kidney tumors with a rapamycin derivative | |
| AU2014299699B2 (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
| KR20160078987A (ko) | 플리나불린 및 탁산의 조합에 의한 암 치료 | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| JP2012528079A (ja) | 癌を治療するためのインテグリンリガンドの連続投与 | |
| US8921367B2 (en) | Use of AMG 900 for the treatment of cancer | |
| US20220241294A1 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
| AU2022381992A1 (en) | Lurbinectedin and atezolizumab combinations | |
| US11911374B2 (en) | Methods and uses for treating cancer | |
| WO2025217597A1 (en) | A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation | |
| JP6643978B2 (ja) | 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ | |
| WO2024105049A1 (en) | Lurbinectedin and doxorubicin combination | |
| WO2025242031A1 (zh) | 吡啶并[2,3-d]嘧啶-2(1H)-酮类衍生物联合用药在治疗和预防肿瘤疾病中的用途 | |
| TW201540296A (zh) | 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231205 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250513 Comment text: Request for Examination of Application |